IMTX - Immatics

-

$undefined

N/A

(N/A)

Immatics NASDAQ:IMTX Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Location: Paul Ehrlich-Strasse 15, Baden Wuerttemberg, 72076, Germany | Website: immatics.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

742.9M

Cash

158.1M

Avg Qtr Burn

-4.319M

Short % of Float

10.71%

Insider Ownership

22.17%

Institutional Own.

69.86%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ACTengine® IMA203 GEN1 (PRAME) Details
Cancer, Solid tumor/s, Melanoma

Phase 3

Initiation

TCER® IMA402 (PRAME) Details
Solid tumor/s, Cancer

Phase 1/2

Data readout

ACTengine® IMA203CD8 GEN2 (PRAME) Details
Solid tumor/s, Cancer, Melanoma

Phase 1b

Data readout

Phase 1

Data readout

ACTengine IMA201 Details
Solid tumor/s, Cancer

Failed

Discontinued

ACTengine IMA202 Details
Cancer, Solid tumor/s

Failed

Discontinued